首页 正文

JAK Inhibitors and Risk of Cancer in IBD Patients

{{output}}
Janus kinase inhibitors, including tofacitinib, filgotinib, and upadacitinib, have emerged as effective therapeutic options for the management of inflammatory bowel diseases (IBDs). By targeting the JAK-STAT signaling pathway, these agents modulate immune resp... ...